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Background and Purpose: The sphingosine analogue, FTY720 (GilenyaR) alleviates clinical 
disease progression in multiple sclerosis.  Here we variously assessed the effects of an azide 
analogue of (S)-FTY720 vinylphosphonate (compound 5; a sphingosine kinase 1 activator), (R)-
FTY720 methyl ether (ROMe, a sphingosine kinase 2 inhibitor) and RB-020 (a sphingosine kinase 
1 inhibitor and sphingosine kinase 2 substrate) on IL-1E formation, sphingosine 1-phosphate 
levels and S1P1 expression.  We also assessed the effect of compound 5 and ROMe in an 
experimental autoimmune encephalomyelitis (EAE) model.  
Experimental Approach:  We measured IL-1E formation by macrophages, sphingosine 1-
phosphate levels and S1P1 expression levels in vitro and clinical score and inflammatory cell 
infiltration into the spinal cord in vivo.   
Key Results: Treatment of differentiated U937 macrophages with compound 5, RB-020 or 
sphingosine (but not ROMe) enhanced IL-1E release. This data suggests these compounds might 
be pro-inflammatory in vitro.  However, compound 5 or ROMe reduced disease progression and 
infiltration of inflammatory cells into the spinal cord in EAE and ROMe induced a reduction in 
CD4+ and CD8+ T-cell levels in the blood (lymphopenia).  Indeed, ROMe induced a marked 
decrease in cell surface S1P1 expression in vitro.  
Conclusion and Implications: This is the first demonstration that an activator of SK1 (compound 
5) and an inhibitor of SK2 (ROMe, which also reduces cell surface S1P1 expression) have an anti-
inflammatory action in EAE. 
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Introduction 
 Sphingosine 1-phosphate (S1P) is formed by the phosphorylation of sphingosine and this 
reaction is catalysed by two isoforms of sphingosine kinase (SK1 and SK2), which are encoded by 
different genes and exhibit distinct subcellular localisations, biochemical properties and functions 
(see Pyne & Pyne, 2011 for review). Once produced, S1P can either be exported from cells 
(through transporter proteins e.g. Spns2 and certain ABC transporters) and act as a ligand on a 
family of five S1P-specific G protein coupled receptors (S1P1-5) (Blaho & Hla, 2014) or, if 
retained within the cell, bind to and regulate specific intracellular target proteins. For instance, 
SK2 catalyses the formation of S1P in the nucleus and the subsequently formed S1P inhibits 
HDAC1/2 activity to induce c-fos and p21 expression (Hait et al., 2009).    
 There is a strong link between S1P and multiple sclerosis (MS), which involves reactive T-
lymphocytes in an autoimmune inflammatory demyelinating disease. Indeed, the sphingosine 
analogue FTY720 is licensed for oral treatment of relapsing MS under the trade name GilenyaTM. 
FTY720 is a pro-drug, which is phosphorylated by SK2 and functionally antagonises sphingosine 
1-phosphate receptor 1 (S1P1), resulting in its proteasomal degradation and removal from T-
lymphocytes (Hla and Brinkmann, 2011). This traps the T-lymphocytes in lymph nodes as they 
cannot egress due to their inability to sense an S1P gradient, which requires surface expression of 
S1P1 on the T cell. The consequence of this is to prevent T-cell action on the CNS in MS.   
 Innate immunity to pathogens employs pathogen-associated molecular patterns (PAMPs) in 
inflammatory cells to stimulate IL-1E and IL-18 release (Schroder & Tschopp, 2010; Takeuchi & 
Akira, 2010). Danger-associated molecular patterns (DAMPs) that include sphingosine, released 
from dead cells, also induce innate immune responses (Chen & Nunez, 2010) by activating the 
NLRP3 ((NOD-like receptor family, pyrin domain containing 3) inflammasome.  This involves 
assembly of apoptosis-associated speck-like protein containing a caspase recruitment domain 
(ASC) with the inflammasome. Caspase-1 is then recruited to the complex where it cleaves pro-
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IL-1E to produce IL-1E (Brough & Rothwell, 2007).  There is also a link between Nlrp3 and 
multiple sclerosis (MS) and between NLRP3 and sphingosine.  Thus, IL-1E levels, Nlrp3 gene 
mutation and MS-like lesions are correlated in the central nervous system (CNS) (Compeyrot-
Lacassagne et al., 2009; Dodé, et al., 2002). Indeed, Nlrp3-/- mice exhibit milder symptoms in 
experimental autoimmune encephalomyelitis (EAE), an animal model for MS disease.  In 
addition, sphingosine and the sphingosine analogue, FTY720 (2-amino-2-[2-(4-
ocytlphenyl)ethyl]-1,3-propanediol) stimulate NLRP3-dependent release of IL-1E from LPS-
stimulated macrophages (Luheshi et al. 2012). We also reported that sphingosine stimulates the 
caspase-1-dependent release of IL-1E from differentiated U937 macrophages via a mechanism that 
involves cathepsin B and lysosomal destabilisation (Boomkamp et al., 2016).  The pro-
inflammatory action of FTY720, in terms of promoting IL-1E release, and its anti-inflammatory 
action, in terms of inhibiting T-cell trafficking therefore appear opposed, although the latter is 
linked with the clinical efficacy of FTY720 in MS.  
 We have previously synthesised an azide analogue of (S)-FTY720 vinylphosphonate (a pan-
S1P receptor antagonist (Valentine et al., 2011)): compound 5 ((S,E)-3-azido-3-(hydroxymethyl)-
5-(4-octylphenyl)pent-1-enylphosphonic acid), which activates SK1 in lysates of HEK 293 cells 
over-expressing this enzyme and therefore is either a direct or indirect effect (Liu et al., 2013). 
Similarly, we have synthesised (R)-FTY720 methyl ether (ROMe; (R)-2-amino-2-
(methoxymethyl)-4-(4-octylphenyl)butan-1-ol), which is a SK2 selective inhibitor (Lim et al., 
2010) and RB-020 (1-(4-Octylphenethyl)piperidin-4-yl)methanol), which is a SK1 inhibitor and a 
SK2 substrate (Baek et al., 2013).  Since these compounds are FTY720 analogues, we variously 
assessed their effect on IL-1E release, S1P levels and S1P1 expression and compared the effect of 
compound 5 and ROMe in an experimental autoimmune encephalomyelitis (EAE) model of MS.  
In this regard, we have previously shown that PF-543 (which is an inhibitor of SK1 (Schnüte et 
al., 2012)) exacerbated EAE disease progression (Pyne et al., 2016).  We have therefore tested the 
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hypothesis that compound 5 (SK1 activator) might abrogate EAE disease progression due to 
enhanced anti-inflammatory activity of SK1, particularly as this might offer novel approaches for 
therapeutic intervention in MS. 
 
Methods 
Cell Culture 
All cells were maintained DW(?&LQDKXPLGLILHGDWPRVSKHUHFRQWDLQLQJ(v/v) CO2.  U937 
monocytic cells (ATCC) were maintained in Roswell Park Memorial Institute (RPMI) medium, 
supplemented with 10% (v/v) foetal bovine serum, 100 U/ml penicillin, (?ȝg/ml streptomycin 
and 2 mM L-glutamine (complete RPMI) and differentiated to macrophages using phorbol 12-
myristate 13-acetate (PMA) as previously described by others (Boomkamp et al., 2016; Shepherd 
et al. 2004; Twomey et al. 1993). Briefly, cells were plated at 1 × 106 cells/ml in complete RPMI 
supplemented with 4 nM PMA. Medium was replenished after two days. After 4 days, the cells 
were cultured in complete RPMI in the absence of PMA for a further 24 hours. It is standard 
practice to differentiate U937 myeloid to macrophages to study inflammatory responses e.g. IL-1E 
release. 
Human lung microvascular endothelial cells (HLMVECs) (Lonza, San Diego, CA, USA) 
were cultured in complete endothelial basal media (EBM-2) containing the growth factors and 
10% (v/v) foetal bovine serum. Contact inhibited monolayers revealed typical cobblestone 
morphology and stained positive for acetylated LDL uptake.  
CCL39 (Chinese hamster fibroblast) cells that were stably transfected with myc-tagged S1P1 
(Rutherford et al., 2013) were maintained in 'XOEHFFR¶V0RGLILHG(DJOH¶V0HGLXPDMEM) with 
GlutaMAXTM VXSSOHPHQWHG ZLWK  YY IRHWDO ERYLQH VHUXP (?U/ml penicillin and 
(?ȝg/ml streptomycin. Cells grown to confluence on 12 well plates were quiesced for 24 hours 
prior to treatment with FTY720 (100 nM) or compound 5 (10 PM) or RB-020 (0.1-10 PM) or 
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ROMe (0.1-10 PM) for 24 hours. Cell lysates were analysed by SDS-PAGE and western blotted 
for proteins of interest (see below). CCL39 cells are used as standard for over-expression of 
recombinant proteins (S1P1) in order to allow testing of compounds for target engagement. 
LNCaP-AI (androgen-independent) prostate cancer cells were maintained in RPMI 
supplemented with 1% (v/v) L-glutamine, 100 U/ml penicillin, 100 Pg/ml streptomycin and 10% 
(v/v) lipid-stripped foetal calf serum.  LNCaP-AI cells are used as a model system since the effect 
of SK1 and SK2 inhibitors on SK1 expression in these cells is well established (Tonelli et al., 
2010, McNaughton et al., 2016). 
 
Interleukin-1E release 
U937 cells were either untreated or treated with the indicated compounds alone for 1 hour or 
stimulated with 1 µg/ml LPS for 2 hours followed by the compounds, as indicated, for 1 hour. A 
series of experiments was performed with matched control and LPS treatments (where indicated) 
but in which not all compounds were necessarily assessed at the same time. Supernatants were 
collected and assayed for IL-ȕ SURWHLQ H[SUHVVLRQ E\ (/,6$ DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V
instructions (Boomkamp et al., 2016). 
  
Western Blotting 
Following treatment, cells were lysed in sample buffer (62.5 mM Tris-HCl (pH 6.7), 0.5 M 
sodium pyrophosphate, 1.25 mM EDTA, 1.25% (w/v) sodium dodecyl sulphate, 0.06% (w/v) 
bromophenol blue, 12.5% (v/v) glycerol and 50 mM dithiothreitol). Proteins were separated on a 
10% (v/v) acrylamide/bisacrylamide gel, and transferred to a nitrocellulose Hybond membrane.  
Membranes were blocked in 5% (w/v) bovine serum albumin (BSA) in TBST buffer (20mM Tris-
HCl (pH 7.5), 48mM NaCl, 0.1% (v/v) Tween20) for 1 hour at room temperature prior to 
incubation with anti-myc tag primary antibody (diluted in blocking buffer) to detect myc-tagged 
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S1P1 overnight at 4ºC. Following three washes in TBST, membranes were incubated with HRP-
conjugated anti-IgG secondary antibody (diluted in blocking buffer) for 1 hour at room 
temperature. Immunoreactive protein bands were visualized using enhanced chemiluminescence.  
Blots were stripped and re-probed for ERK-2 or actin to ensure equal protein loading (Boomkamp 
et al., 2016). 
 
FACS Analysis 
Peripheral blood from naive, control or compound 5- or ROMe-treated mice was collected into EDTA 
to prevent clotting and red blood cells removed with RBC lysis buffer (eBioscience).  Cells were added to 
FACS tubes (0.5x106 cells per tube) and incubated (30 minutes in the dark at 4°C) with FITC-
conjugated anti-CD4 and PerCP-Cy5.5-conjugated anti-CD8 (1:500 dilution).  Cells were washed 
and resuspended in 0.5 ml FACS buffer (1 % (w/v) BSA in phosphate buffered saline (PBS)) prior 
to quantification using a BD FACSCanto system and BD FACSDiva software (BD Biosciences).  
Similarly, CCL39 cells, grown in 12 well plates, were treated with vehicle (DMSO) or 
compounds, as described in the figure legends. These cells were added to FACS tubes (0.2x105 
cells per tube) and incubated with allophycocyanin (APC)-conjugated S1P1 antibody (1:50 
dilution; 30 minutes in the dark at 4°C).  Cells were washed twice with FACS buffer, resuspended 
in 0.25 ml FACS buffer with 12.5 µl propidium iodide (to allow exclusion of dead cells) and 
quantified.  
 
S1P measurement 
HLMVECs, cultured in 35 mm dishes to ~90% confluence, were labelled with 40 PCi/ml of [32P] 
orthophosphate in phosphate free DMEM medium for 3 h.  The radioactive medium was aspirated 
and cells incubated with vehicle (DMSO) or the compounds for 1 h in phosphate free DMEM 
medium containing 0.1% (w/v) fatty acid free BSA (1 ml final volume) for 1 h prior to addition of 
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exogenous sphingosine (2 PM) in 0.1% (w/v) fatty acid free BSA for an additional 1 h. Lipid were 
extracted by addition of 1 ml methanol containing 1% (v/v) 12 N HCl, scraped into tubes followed 
by an additional 1 ml of methanol containing 1% (v/v) 12 N HCl.  To this methanolic extract, 2 ml 
of CHCl3 and 1 ml of 0.1N NaOH were added, vortexed and the lower CHCl3 layer collected, 
dried under N2 and subjected to TLC for S1P separation and quantification (Tonelli et al., 2013). 
 
EAE Mouse Model 
C57BL/6 mice were purchased from Harlan (Oxford, UK) and maintained at the Biological 
Procedure Unit, University of Strathclyde. All experiments were performed under the guidelines 
of the UK Home Office Animals (Scientific Procedures) Act 1986 and were compliant with the 
ARRIVE guidelines for experiments involving animals (McGrath et al., 2010). Female mice at the 
age of 7±12 weeks were used in all experiments. 
 
EAE Induction and Clinical Evaluation 
EAE induction was performed as previously described (Jiang et al., 2009).  Mice were 
immunized subcutaneously on the back with 100 Pg of Myelin Oligodendrocyte Glycoprotein 
Peptide Fragment 35-55 (MOG35-55) in 100 µl of PBS emulsified with an equal volume of 
&RPSOHWH)UHXQG¶V$GMXYHQW(CFA, total 350 Pg of Mycobacterium tuberculosis, strain H37RA).  
Each mouse also received intraperitoneally (i.p.) 100 ng/100 Pl of pertussis toxin (PTX) in PBS on 
days 0 and 2 post immunization. EAE was scored according to a 0 - 5 scale as follows: 0, no 
clinical sign; 1, complete loss of tail tone; 2, hind limb weakness; 3, hind limb paralysis; 4, 
forelimb involvement; 5, moribund.  In a previous study (in house), the maximum clinical score in 
EAE mice was 2.625 ± 0.7048 (mean ± SD, n=20).  Assuming a change in clinical score of 1.4 to 
be of clinical relevance, the number of mice required to detect this at 80% statistical power (2 
sided, 5% significance) was calculated to be 6 mice per group.  18 females from separate litters 
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born within 5 days of each other were used.  These were then randomly divided them into 3 cages 
of 6 and each cage randomly designated to a specific treatment (Cage A = compound 5, Cage B = 
ROMe and Cage C = vehicle) in a non-blinded manner (due to available expertise). 
To confirm that the infiltration of immune cells in the spinal cord tissue and subsequent 
inflammation and demyelination was EAE specific, control mice were immunised with a similar 
protocol including CFA and PTX, but with PBS in place of MOG35-55 peptide. Our data show that 
these mice displayed no signs of clinical disease, sickness or discomfort, and they gained weight 
throughout the course at a rate similar to naïve mice.  The total number of mice employed in the 
study was 28. 
 
 Preparation of Compounds, Dosage and Route of Administration 
All compounds were dissolved in a vehicle solution of 20% cyclodextrin in PBS. Compound 
5 was prepared as a 1.55 mg/ml stock. The dosage given was 12.4 mg/kg (the approximate in vivo 
concentration is 30 PM assuming 100% bioavailability). ROMe was prepared as a 0.404 mg/ml 
stock. The dosage given was 3.234 mg/kg (the approximate in vivo concentration is 10 PM 
assuming 100% bioavailability).  The dose of compound 5 and ROMe used in the EAE model was 
based on the EC50/IC50 for SK activation/inhibition, respectively (Liu et al., 2013; Lim et al., 
2010), and assumed 100% bioavailability. The compounds were all administered i.p. daily from 
day 0 of MOG33-55 immunization at the above doses. The EAE vehicle control group received i.p. 
injection daily of the 20% cyclodextrin vehicle.  
 
Immunohistochemical Staining 
Mice were euthanized in a CO2 chamber and their spinal cords flushed out with PBS by 
hydrostatic pressure using a 19G syringe. Tissues were immediately frozen in OCT and 8Pm thick 
sections were stained with specific primary antibodies for CD4, CD45 and F4/80 overnight. 
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Sections were then washed and incubated with biotinylated secondary antibody and streptavidin-
HRP before being detected with ImmPACT AMEC red peroxidise substrate.  Sections were then 
washed in distilled water and counterstained with haematoxylin. Isotypes with matching IgG were 
used as negative control and showed no staining in all tissues.  
 
Statistical analysis 
Statistical analysis employed unpaired t-test, one-way ANOVA with Bonferroni post-test, two-way 
ANOVA with Bonferroni post-test or repeated measures ANOVA (using GraphPad PrismTM, V4.0, 
(GraphPad Software, San Diego)), as appropriate and as indicated in the figure legends.  Data was 
considered to be significant when p < 0.05. Values of n for in vitro experiments are derived from 
independent experiments rather than within-experiment replicates.  Densitometric values 
(represented as mean +/- SD) were normalized using the corresponding data for actin for the same 
samples and were obtained from 5 independent experiments. Statistical analysis was undertaken 
using one way ANOVA with Tukey's post hoc test. 
 
Materials 
Cell culture media (RPMI, DMEM with GlutaMAXTM) and supplements (penicillin, 
streptomycin, L-glutamine) were obtained from Life Technologies (Paisley, UK). Foetal bovine 
serum was from Seralabs (Sussex, UK).  Fine chemicals including phorbol 12-myristate 13-acetate 
(PMA), lipopolysaccharide (LPS), the caspase-1 inhibitor (Ac-YVAD-CHO), PP2A inhibitor 
(okadaic acid), pertussis toxin, cyclodextrin, HRP-conjugated anti-mouse IgG secondary antibody 
and haematoxylin were from Sigma (Poole, UK); propidium iodide was from eBioscience 
(Altrincham, UK). Antibodies employed included anti-myc (to detect myc-tagged S1P1) (# sc-40, 
Santa Cruz, Wembley, UK), ERK-2 (# 610104, Transduction Laboratories, Oxford, UK), actin (# 
A2066, Sigma, Poole, UK), anti-S1P1-APC (# FAB7089A, R & D Systems, UK),  biotinylated 
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secondary antibody, anti-CD4, anti-CD45 and anti-F4/80 and streptavidin-HRP (eBioscience, 
Hatfield, UK).  ImmPACT AMEC red peroxidise substrate was from Vector Laboratories, 
Peterborough, UK.  Dithiothreitol was purchased from Enzo (Exeter, UK), nitrocellulose Hybond 
membrane  from GE Healthcare (Little Chalfont, UK) and IL-ȕSURWHLQ(/,6$ kits from  R&D 
Systems (Abingdon, UK), Myelin Oligodendrocyte Glycoprotein Peptide Fragment 35-55 
(MOG35-55) (Sigma Genosys, Haverhill, UK) and &RPSOHWH )UHXQG¶V $GMXYHQW IURP 'LIFR
(Detroit, MI).  Compound 5, RB-020 and ROMe were synthesized as described previously (Liu et 
al., 2013; Lim et al., 2010; Baek et al., 2013). Compound 5 was gifted by Young Ah Kim (City 
University of New York). 
 
Results  
Effect of compound 5 and RB-020 on IL-1E release 
We have previously shown that the azide analogue of (S)-FTY720 vinylphosphonate 
(compound 5) is an activator of SK1 and is not a substrate for either SK1 or SK2 (Liu et al., 
2013).  We have also shown that RB-020 is an SK1 inhibitor and SK2 substrate (Baek et al., 
2013) and that (R)-FTY720 methylether (ROMe) has a Ki =16 PM for SK2 inhibition (Lim et al., 
2011) with no inhibitory effect on SK1 at concentrations of 100 PM. See Fig. 1A for chemical 
structures.  In addition, we have previously shown that SK1 inhibitors induce the proteasomal 
degradation of SK1 to create SK1 null cells (Tonelli et al., 2010; McNaughton et al, 2016).  In 
androgen-sensitive prostate cancer cells, this can lead to apoptosis (Loveridge et al., 2010).  
Therefore, we tested the effect of compound 5, RB-020 and ROMe on SK1 expression levels in 
androgen-independent LNCaP-AI prostate cancer cells.  We show here that the SK1 inhibitor, RB-
020 induces a decrease in SK1 expression in LNCaP-AI cells but, as expected, the SK1 activator, 
compound 5 (10 PM) and the SK2 inhibitor, ROMe (0.1-10 PM) were without effect on SK1 
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expression (Fig. 1B).  These findings are consistent with previous findings which demonstrate that 
the proteasomal degradation of SK1 is associated with SK1 inhibitors.  
We have previously shown that ROMe modulates cellular sphingolipid levels with a 
reduction in S1P and an increase sphingosine levels (Watson et al., 2013).  Here we show that the 
SK1 inhibitor/SK2 substrate RB-020 and the SK1 selective nM potent inhibitor, PF-543 (Schnüte 
et al., 2012) reduce intracellular S1P, formed from exogenously added sphingosine in HLMVECs 
(Fig. 1C).  In contrast, compound 5 increased S1P formation from exogenously added sphingosine 
in HLMVECs (Fig. 1C), consistent with this compound functioning as an activator of SK1 in 
these cells. Compound 5 activates recombinant SK1 by ~ 50% at 30 PM in lysates from HEK 293 
cells over-expressing this enzyme (Liu et al., 2013) and this is consistent with the 28% increase in 
S1P formed from exogenously added sphingosine (Fig. 1C).  Interestingly RB-020 is very heavily 
phosphorylated in HLMVECs (phosphorylated RB-020: 30527 ± 2304 dpm per 106 dpm in total 
phospholipids), consistent with our previous finding that RB-020 is a substrate for purified SK2 
(Fig. 1C, Baek et al., 2013).    
Given their chemical similarity with FTY720, we investigated the effect of compound 5 or 
sphingosine or RB-020 on IL-1E release from macrophages. We show here that treatment of 
differentiated U937 cells with compound 5 (10 PM) or FTY720 (10 PM) or sphingosine (20 PM) 
significantly increased IL-1E release and IL-1E release showed an upward trend in the presence of 
RB-020 (10 PM) (p = 0.06, Fig. 2A).   There is evidence that PAMPs (e.g. LPS/TLR4) and 
DAMPs (e.g. sphingosine) can functionally interact to regulate NLRP inflammasome activity and 
IL-1E formation (Netea et al., 2009; Escamilla-Tilch et al., 2013; Luheshi et al. 2012).  Therefore, 
we tested the effect of the compounds in the presence of LPS.  LPS stimulated IL-1Erelease in 
differentiated U937 macrophages (Fig. 2B).  Moreover, treatment of these cells with compound 5 
(10 PM), FTY720 (10 PM) or RB-020 (10 PM) increased IL-1E release in the presence of LPS 
(Fig. 2B, upper panel). The effects of compound 5 was not additive with sphingosine (Fig. 3), 
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suggesting a common mechanism of action for this effect.  To investigate whether sphingosine 
kinase inhibitors increase IL-1E release, we tested the effect of the SK2 selective inhibitor, ROMe 
and the SK1/2 inhibitor SKi, (2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole).  We have 
previously demonstrated that ROMe (SK2 inhibitor) has no effect on LPS-induced IL-1E release 
(Boomkamp et al., 2016) and this is shown here (Fig. 2B, lower panel).   In addition, SKi had no 
effect on IL-1E release in the presence of LPS (Fig. 2B, lower panel).   The effect of compound 5 
on IL-1E release in the presence of LPS was reduced by pretreatment of cells with the caspase-1 
inhibitor, Ac-YVAD-CHO (Fig. 4A), thereby confirming a role for the inflammasome.  Finally, 
treatment of cells with the PP2A inhibitor, okadaic acid (0.5 PM), had no effect on the ability of 
compound 5  to increaseIL-1E release in the presence of LPS (Fig. 4B). 
 
Effect of compound 5 and ROMe on disease progression in EAE 
We have previously shown that PF-543 (which is a nM potent inhibitor of SK1) exacerbates EAE 
disease progression (Pyne et al., 2016).  Therefore, we tested the effect of the SK1 activator, 
compound 5 on EAE disease progression and compared it with the SK2 inhibitor, ROMe.  Both 
compound 5 and ROMe markedly reduced EAE disease progression (clinical score) (Fig. 5A). The 
efficacy of these compounds is remarkable with 11 out of 12 mice exhibiting no symptoms 
whatsoever.  EAE mice have a massive infiltration of immune cells in the spinal cord, which was 
not evident in PBS control tissues (Fig. 5B), confirming that the presence of immune cells in the 
CNS was EAE specific. Compound 5 or ROMe induced a considerable decrease in leukocyte 
infiltration including CD45+ leukocytes, CD4+ T-cells and F4/80+ macrophages in the spinal cord 
of EAE mice (Fig. 5B). Immunohistochemical staining of spinal sections demonstrated that there 
are no infiltrating inflammatory cells in mice treated with compound 5 or ROMe (Fig. 5B). In 
addition, ROMe (but not compound 5) induced a reduction in CD4+ and CD8+ T-cell levels in the 
blood (lymphopenia) (Fig. 5C).   
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Effect of compound 5 and RB-020 on S1P1 expression 
Since FTY720, when converted by SK2 to FTY720-phosphate, is a functional antagonist of 
S1P1 (by inducing proteasomal degradation of S1P1) and this underlies part of its action in 
alleviating MS disease progression (Bigaud et al., 2014), we assessed the effect of compound 5, 
RB-020 or ROMe on S1P1 expression levels in CCL39 cells that stably over-express myc-tagged 
S1P1 (Boomkamp et al., 2016).  This expression system is used for analyzing S1P1 modifying 
agents as it is very well established that FTY720 (specifically FTY720 phosphate) induces 
proteasomal degradation of S1P1 (Oo et al., 2007).  In common with FTY720, which significantly 
reduced EAE severity in mice and S1P1 levels in CCL39 cells (Boomkamp et al. 2016), 
compound 5, RB-020 or ROMe (0.1-10 PM) induced a reduction in S1P1 levels (Supplementary 
Fig. 1). Indeed, proteolytic fragments of S1P1 were detected in cells treated with compound 5 or 
RB-020 (Supplementary Fig. 1). We also assessed the cell surface expression of S1P1 on CCL39 
cells by FACS analysis.  Treatment of CCL39 cells with RB-020, ROMe (0.1-10 PM) or FTY720 
induced a 70-80% reduction cell surface expression of S1P1 while compound 5 induced a ~ 40% 
reduction (Fig. 6).  Therefore, the ROMe-induced reduction in CD4+ and CD8+ T-cell levels in the 
blood might be determined by a threshold cell surface S1P1 expression level. 
 
Discussion  
We have presented in vivo data to show that ROMe and compound 5 exhibit remarkable 
efficacy in reducing disease progression in an EAE model.  However, the mechanisms by which 
this occurs differ.  We demonstrate that compound 5 (unlike ROMe) does not induce a reduction 
in CD4+ and CD8+ T-cells levels in the blood.  Indeed, ROMe recapitulates the effect of FTY720 
(in use for MS therapy (as GilenyaR)) in substantially reducing cell surface S1P1 expression (> 
70%) in CCL39 cells.  Therefore, it is possible that the effect of ROMe on EAE progression 
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involves modulation of S1P1 and inhibition of T-lymphocyte trafficking from lymph nodes.  
However, the effects on EAE disease progression might also be related to the ability of ROMe to 
inhibit SK2 (Fig. 7), which is known to affect gene expression (Hait et al., 2009), as this 
compound induces a marked reduction in the infiltration of leukocytes and F4/80 macrophages 
into the spinal cord of EAE mice. Indeed, SK2 knockout mice are protected from EAE and this is 
associated with a partial lymphopenia (Imeri et al., 2016).  In addition, S1P enhances the 
development of Th17 cells (Liao et al., 2007), which are implicated in the pathogenesis of MS and 
it is possible that SK2 regulates this compartment specific pool of S1P. Th17 cells were found 
primarily within central memory T cells and FTY720 reduced blood central memory T cells, 
including RORJt and IL-17-producing T cells, by >90% (Mehling et al., 2010).  S1P also inhibits 
Tregs function, thereby preventing the suppressive effect of Tregs on Th17 formation (Liu et al., 
2009).  Therefore, inhibition of S1P formed by SK2 might block these processes to alleviate EAE 
disease progression.  There is also close link between Th17 and Th1.  Indeed, Th1 cells can be 
formed from Th17 (Harbour et al., 2015). In this regard, IL-12 is a Th1 cytokine and the IL12E1 
receptor associates with SK2 and increases IL-12-induced STAT4-mediated transcriptional 
activity while dominant negative SK2 in Th1 cells reduced IL-12 stimulated IFNJ formation and 
WT SK2 enhanced it (Yoshimoto et al., 2003).  Finally, the SK2 inhibitor, ABC294640 has been 
shown to be anti-inflammatory, consistent with the findings here with ROMe.  ABC294640 
reduced TLR4 expression, NF-ț% DFWLYDWLRQ SUR-inflammatory cytokine/chemokine production, 
adhesion molecule expression and the infiltration of monocytes/macrophages and neutrophils (Liu 
et al., 2012). 
The lack of effect of the SK1 activator, compound 5 on CD4+ and CD8+ cell levels in the 
blood is consistent with its lesser effect on cell surface expression of S1P1 in CCL39 cells, i.e. 
S1P1 levels may not fall below a threshold  required to prevent egress from lymph nodes in vivo.  
The mechanism by which compound 5 affects S1P1 expression levels might involve direct binding 
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of this compound to the receptor and subsequent degradation of the receptor (Fig. 7).  This is 
based on the finding that the parent compound, (S)-FTY720 vinylphosphonate is able to bind to 
and antagonise S1P1 (Valentine et al., 2010).  However, the effect of compound 5 in vivo involves 
a novel anti-inflammatory mechanism of action that is distinct from that of FTY720, whereby SK1 
regulates a compartment specific pool of S1P which functions in an ant-inflammatory manner 
(Fig. 7).  This is supported by the demonstration that SK1 is a negative regulator of Th1 and Th0 
cells and siRNA knockdown of SK1 enhances IL-2, TNFD and IFNJ release in response to TCR 
stimulation (Yang et al., 2005).  Moreover, over-expression of SK1 reduces these effects in 
response to TCR stimulation (Yang et al., 2005).  In addition, the loss of SK1 potentiates 
induction of the pro-inflammatory chemokine RANTES and multiple chemokines and cytokines 
(Adada et al., 2013).  Significantly our findings are the first to demonstrate that an activator of 
SK1 has this (or any) effect in vivo.   
The effect of compound 5 on disease progression in the EAE model does not appear to be 
hindered by its stimulatory effects on IL-1E release, as detected in an in vitro cellular system (Fig. 
7). Indeed, the major effect of RB-020 and compound 5 on IL-1E release more likely relates to 
their ability to mimic sphingosine and FTY720 and this is supported by the finding that both 
sphingosine and FTY720 enhance LPS-stimulated IL-1E release. However, SK inhibitors such as 
ROMe or SKi do not increase IL-1E.  One possible explanation is that these SK inhibitors might 
not induce sufficient accumulation of sphingosine and/or promote sphingosine formation in the 
correct cellular compartment where IL-1Eprocessing occurs.  In addition, despite structural 
similarity to FTY720, the failure of ROMe to induce IL-1E release suggest that the 3-OH group in 
FTY720 and sphingosine is required for inflammasome-dependent stimulation of IL-1E release.   
The effectiveness of ROMe and compound 5 in reducing EAE disease progression is 
consistent with a pharmacological mode of action on S1P signalling.  We therefore conclude that 
combined modulation of SK1 (activation) and SK2 activity (inhibition) and S1P1 (down-
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regulation) might provide an effective anti-inflammatory action to ablate disease progression in 
multiple sclerosis.  Our data is also consistent with the partial protection from EAE observed in 
inducible Sgpl1 (S1P lyase) knockout mice (Billich et al., 2013) and the anti-inflammatory effect 
of S1P lyase inhibitors (Bagdanoff et al., 2010). 
Therefore, we have demonstrated that compound 5 exhibits a novel mechanism of action 
compared with FTY720 and this provides the rationale for future development of SK1 activators 
in the treatment of MS.   
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Figure legends  
Figure 1. Chemical structures and effects on SK1 expression and S1P formation in 
cells.  (A) Chemical structures of FTY720, compound 5, RB-020 and ROMe. (B) Western blot 
showing the effect of compound 5 (10 PM), RB-020 (10 PM) and ROMe (10 PM) on the 
expression levels of SK1 in LNCaP-AI cells. Actin was used as a loading control.  Results are 
representative of 5 independent experiments.  Also shown is the densitometric quantification 
represented as a bar graph.  * p < 0.05 versus control.  (C) Bar graphs showing the effect of 
compound 5 (30 PM), RB-020 (10 PM) and PF-543 (100 nM) on S1P formation from 
exogenously added sphingosine in HLMVECs.  Results are expressed as means +/- SD for three 
independent experiments * p < 0. 05 (one-way ANOVA with Bonferroni post-test; basal [32P]S1P 
= 718 + 169dpm;  plus sphingosine [32P]S1P = 6154 + 569 dpm). 
Figure 2.  Compound 5, RB-020 and FTY720, but not ROMe or SKi, enhance IL-ȕ
release in the presence and absence of LPS in differentiated U937 cells.  Differentiated U937 
cells were treated with (A) sphingosine (20 µM) , compound 5, FTY720 or RB-020 (all at 10 µM) 
alone for 2 hours or (B) LPS (1 µg/ml) for 2 hours and compound 5, RB-020, FTY720, ROMe or 
SKi (all at 10 µM) for a further 1 hour and the supernatants assayed by ELISA for IL-ȕreleased 
(pg/ml).  (A) Results are expressed as means +/- SEM for independent experiments with matched 
controls (n=5 for Sph, FTY720, RB-020 and n=6 for compound 5); * p < 0.05 versus control using 
an unpaired t-test. (B) Results are expressed as means +/- SEM for independent experiments with 
matched controls and LPS (n=5, ROMe panel; n=6, compound 5, RB-020 and SKi panels; n=8; 
FTY720 panel); * p < 0.05 versus control using one-way ANOVA with 'XQQHWW¶V post-test; ** p < 
0.05 versus /36UHVSRQVHDQGQRWVLJQLILFDQWversus LPS response using one-way ANOVA with 
Bonferroni post-test. 
Figure 3. Sphingosine or compound 5 enhances IL-ȕUHOHDVHLQWKHSUHVHQFHRI/36
in a non-additive manner.  Differentiated U937 cells were treated with LPS (1 µg/ml) for 2 hours 
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and then with sphingosine (20 µM) or compound 5 (10 µM) or both sphingosine and compound 5 
for 1 hour and the supernatants assayed for IL-ȕE\(/,6$Results are expressed as means (IL-
1E (pg/ml) released) +/- SEM for 6 independent experiments.  Statistical analysis was performed 
using one-way ANOVA with Bonferroni post-test. * p < 0.05 versus LPS DORQHQo significant 
difference versus LPS/Sph or LPS/compound 5. 
Figure 4. The effect of the Caspase-1 inhibitor Ac-YVAD-CHO or the PP2A inhibitor, 
okadaic acid on the enhancement of IL-ȕrelease by compound 5 in the presence of LPS. 
Differentiated U937 cells were treated with vehicle or Ac-YVAD-CHO (10 µM) or okadaic acid 
for 15 min (black bars), stimulated with LPS (1 µg/ml) for 2 hours prior to treatment with 
compound 5 (10 µM) for 1 hour and the supernatants assayed for IL-ȕE\(/ISA.  (A) The effect 
of AC-YVAD-CHO on the increase in IL-1E release by compound 5 in the presence of LPS; (B) 
The lack of effect of okadaic acid on the increase in IL-1E release induced by compound 5 in the 
presence of LPS.  Results are expressed as means (IL-1E (pg/ml) released) +/- SEM for 4 (Ac-
YVAD-CHO) or 3 (okadaic acid) independent experiments.  Statistical analysis was performed 
using two-way ANOVA with Bonferroni post-test. No significant difference between 
LPS/Compound 5 versus LPS/compound 5/okadaic acid. * p < 0.05 for LPS/Compound 5 versus 
LPS/compound 5/Ac-YVAD-CHO. 
Figure 5.  Compound 5 or ROMe attenuate disease progression in EAE.  EAE-treated 
mice were treated with vehicle alone or dosed with compound 5 (12.4 mg/kg) or ROME (3.23 
mg/kg).  (A) Clinical scores are plotted against time and are represented as means ± SEM for n=6 
mice/treatment.  Repeated Measures ANOVA was carried out. * p < 0.05 for compound 5 or 
ROMe versus vehicle. (B) Immunohistochemical staining of representative spinal sections with 
specific anti-CD4, anti-CD45 or anti-F4/80 antibodies.  Arrows denote infiltrating cells. Results 
are representative of n=6 mice/treatment.  We have included immunohistochemical staining of 
spinal sections from control mice (representative of results from 10 naïve mice) to show that there 
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are no infiltrating inflammatory cells.  (C) FACS analysis of CD4+ and CD8+ cells.  FACS plots 
are representative of n=6 animals/treatment group for vehicle, compound 5 and ROMe and 3 for 
naïve animals.  Graphs show combined data; bars represent mean ± SEM.  One way ANOVA was 
carried out. * p < 0.05 versus vehicle. 
Figure 6. Analysis of S1P receptor surface expression in CCL39 cells.  FACS analysis 
of CCL39 cells pretreated with compound 5 (30 µM), RB-020 (10 µM), ROMe (100 nM or 10 
µM), or FTY720 (1 µM), on cell surface S1P1 expression.   Graphs show combined data; bars 
represent mean ± SEM for 5 independent (or for 100 nM ROMe, three independent experiments) 
experiments.  One way ANOVA was carried out. * p < 0.05 versus control. 
Figure 7. Schematic summarising the observed effects of ROMe and compound 5 in 
inflammatory cells involved in EAE and multiple sclerosis disease progression 
 
Supplementary Figure 1. The effect compound 5, ROMe and RB-020 on myc-tagged 
S1P1 expression in CCL39 cells.  CCL39 cells stably over-expressing myc-tagged S1P1 were 
treated with FTY720 (100 nM), compound 5 (10 µM), ROMe (0.1-10 µM) or RB-020 (0.1-10 
µM) for 24 h.  Cell lysates were then western blotted with anti-myc antibody. ERK-2 was used as 
a protein loading control.  Results are representative of 3 independent experiments. 
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TARGETS   
Other protein targetsa Enzymese 
PAMP  Sphingosine kinase 1  
DAMP Sphingosine kinase 2  
NLRP3  Sphingosine 1-phosphate lyase  
GPCRsb HDAC1 
S1P1  HDAC2 
 Caspase 1 
 ERK-2 
 Hormone sensitive lipase (HSL)  
 PKA  
 
These Tables of Links list key protein targets and ligands in this article that are hyperlinked* to 
corresponding entries in http://www.guidetopharmacology.org, the common portal for data from 
the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016), and are permanently archived 
in The Concise Guide to PHARMACOLOGY 2015/16 (a,b,c,d,eAlexander et al., 2015a,b,c,d,e). 
 
ABBREVIATIONS 
Compound 5: (S,E)-3-azido-3-(hydroxymethyl)-5-(4-octylphenyl)pent-1-enylphosphonic 
acid; DAMPs, Danger associated molecular patterns; DMEM, Dulbeccos Modified Eagles 
Medium; EAE, experimental autoimmune encephalomyelitis; ERK, extracellular signal 
regulated kinase; FTY720, 2-amino-2-[2-(4-ocytlphenyl)ethyl]-1,3-propanediol; LPS, 
lipopolysaccharide; NLRP3, NOD-like receptor family, pyrin domain containing 3; IFNJ, 
interferon gamma; IL-1E, interleukin-1beta; PAMPs, Pathogen-associated molecular patterns; 
PP2A, protein phosphatase 2A; PP1, protein phosphatase 1; RB-020, 1-(4-
Octylphenethyl)piperidin-4-yl)methanol; ROMe, (R)-FTY720 methyl ether, (R)-2-amino-2-
(methoxymethyl)-4-(4-octylphenyl)butan-1-ol; SK, sphingosine kinase; S1P, sphingosine 1-
phosphate; S1P1, sphingosine 1-phosphate receptor-1; TLR, Toll-like receptors. 
LIGANDS   
FTY720  ROMe  
FTY720 
phosphate  
Sphingosine 1-
phosphate (S1P) 
IL-1E  Lipopolysaccharide 
(LPS) 
IL-18 IL-12 
PF-543  PMA  
Sphingosine 
kinase inhibitor 
(SKi) 
Okadaic acid  
